Boston Scientific (NYSE:BSX) Price Target Raised to $128.00

Boston Scientific (NYSE:BSX) had its price objective boosted by Robert W. Baird from $123.00 to $128.00 in a research report report published on Wednesday, Marketbeat.com reports. Robert W. Baird currently has an outperform rating on the medical equipment provider’s stock.

Other equities analysts have also recently issued research reports about the stock. Leerink Partners initiated coverage on shares of Boston Scientific in a research note on Monday, June 16th. They issued an “outperform” rating and a $118.00 price objective for the company. Raymond James Financial raised their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 24th. Barclays lifted their price objective on Boston Scientific from $125.00 to $133.00 and gave the company an “overweight” rating in a report on Thursday, July 24th. Leerink Partnrs raised Boston Scientific to a “strong-buy” rating in a report on Monday, June 16th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a research note on Monday, September 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $120.79.

Boston Scientific Trading Up 1.1%

Boston Scientific stock opened at $97.30 on Wednesday. The business has a 50 day moving average price of $102.93 and a two-hundred day moving average price of $102.05. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific has a 12 month low of $80.64 and a 12 month high of $109.50. The stock has a market cap of $144.17 billion, a price-to-earnings ratio of 57.91, a price-to-earnings-growth ratio of 2.32 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific’s quarterly revenue was up 22.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities analysts forecast that Boston Scientific will post 2.85 EPS for the current year.

Insiders Place Their Bets

In related news, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director owned 18,479 shares in the company, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the firm’s stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the sale, the director owned 2,081 shares of the company’s stock, valued at $222,646.19. The trade was a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Boston Scientific

Hedge funds have recently added to or reduced their stakes in the company. Jackson Wealth Management LLC lifted its position in Boston Scientific by 2.3% during the 3rd quarter. Jackson Wealth Management LLC now owns 46,765 shares of the medical equipment provider’s stock valued at $4,566,000 after purchasing an additional 1,052 shares during the period. Aaron Wealth Advisors LLC grew its position in shares of Boston Scientific by 60.8% during the 3rd quarter. Aaron Wealth Advisors LLC now owns 17,849 shares of the medical equipment provider’s stock worth $1,743,000 after buying an additional 6,749 shares during the period. West Oak Capital LLC raised its stake in shares of Boston Scientific by 123.1% during the third quarter. West Oak Capital LLC now owns 725 shares of the medical equipment provider’s stock worth $71,000 after buying an additional 400 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Boston Scientific by 12.0% in the third quarter. GAMMA Investing LLC now owns 33,017 shares of the medical equipment provider’s stock valued at $3,223,000 after buying an additional 3,531 shares during the period. Finally, Bank of New Hampshire boosted its stake in Boston Scientific by 9.7% in the third quarter. Bank of New Hampshire now owns 21,636 shares of the medical equipment provider’s stock valued at $2,112,000 after acquiring an additional 1,912 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.